Table 1 Patient characteristics at diagnosis.
Total | Not Subset#2 | Subset#2 | Comparison test | |
|---|---|---|---|---|
(n = 410)a | (n = 185)a | (n = 225)a | (p-value)b | |
Follow-up time (months) | 64 (0–373) | 64 (0–341) | 64 (0–373) | 0.8 |
Age at diagnosis | 66 (30–95) | 67 (36–91) | 64 (30–95) | 0.054 |
Sex | 0.10 | |||
Female | 152 (37%) | 61 (33%) | 91 (41%) | |
Male | 254 (63%) | 123 (67%) | 131 (59%) | |
Binet stage | 0.5 | |||
A (Low risk) | 262 (65%) | 123 (68%) | 139 (63%) | |
B (Intermediate risk) | 90 (22%) | 36 (20%) | 54 (25%) | |
C (High risk) | 50 (12%) | 23 (13%) | 27 (12%) | |
IGHV status | <0.001 | |||
Borderline | 83 (20%) | 18 (9.7%) | 65 (29%) | |
Mutated | 159 (39%) | 73 (39%) | 86 (38%) | |
Not mutated | 168 (41%) | 94 (51%) | 74 (33%) | |
CK or very CK | 53 (13%) | 25 (14%) | 28 (12%) | 0.7 |
TP53 alteration | 0.3 | |||
Altered | 111 (27%) | 54 (29%) | 57 (25%) | |
Not altered | 183 (45%) | 86 (46%) | 97 (43%) | |
Not researched | 116 (28%) | 45 (24%) | 71 (32%) | |
17p deletion | 0.060 | |||
Deleted | 18 (4.4%) | 12 (6.5%) | 6 (2.7%) | |
Not deleted | 392 (96%) | 173 (94%) | 219 (97%) | |
TP53 mutation | 0.5 | |||
Mutated | 101 (25%) | 47 (25%) | 54 (24%) | |
Not mutated | 190 (46%) | 90 (49%) | 100 (44%) | |
Not researched | 119 (29%) | 48 (26%) | 71 (32%) |
